TY  - JOUR

T1  - Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

JO  - PharmacoEconomics

UR  - https://eprints.whiterose.ac.uk/id/eprint/114278

PY  - 2017/08/01

AU  - Tappenden P

AU  - Carroll C

AU  - Stevens JW

AU  - Rawdin A

AU  - Grimm S

AU  - Clowes M

AU  - Kaltenthaler E

AU  - Ingram JR

AU  - Collier F

AU  - Ghazavi M

ED  - 

DO  - DOI: 10.1007/s40273-017-0488-2

PB  - Springer Verlag

VL  - 35

IS  - 8

SP  - 805

EP  - 815

Y2  - 2025/10/31

ER  -